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Purpose: To formulate and evaluate chitosan acetate films designed for transdermal delivery of 
propranolol hydrochloride.  
Methods: Chitosan acetate was chemically modified with acetaldehyde and the solution was prepared 
with 1 % acetic acid, in which was dissolved propranolol hydrochloride, was cast as films in Petri dish 
and characterised by Fourier transform infrared spectroscopy (FTIR), differential scanning calorimetry 
(DSC) and nuclear magnetic resonance (NMR). The films were evaluated for permeability, swelling, and 
in vitro drug release.  
Results: Drug content of propranolol hydrochloride in the films ranged from 0.9 to 1.4 mg/cm
2
 . Swelling 
was 570 % for chitosan acetate and 180 % for chitosan while drug release through chitosan acetate 
higher than through chitosan. Permeability coefficient was 6.12 x 10
-4 




/ day for 
chitosan acetate and chitosan, respectively. FTIR and DSC results indicated that there was no chemical 
interaction between the drug and the polymers used. NMR spectra showed the appearance of specific 
peaks for acetate group. Differences between chitosan acetate and chitosan were significant (p < 0.05) 
with regard to permeability, swelling and in vitro drug release.  
Conclusion: The films prepared using the synthesised chitosan acetate exhibited superior 
physicochemical and drug release characteristics to those of chitosan. The results also indicate chitosan 
acetate films may be suitable for delivering propranolol hydrochloride via the transdermal route which 
offers some advantages over other routes. 
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INTRODUCTION 
 
Chitosan is a linear, semi-rigid 
polysaccharide, which is believed to be a 
promising biomaterial in view of its 
biodegradability, biocompatibility and 
relatively low toxicity. Chitosan is a 
copolymer of N-acetyl D-glucosamine and D-
glucosamine. Chemical modification has 
been attempted to improve water solubility 
and bioactives of the polymer[2]. To improve 
its aqueous solubility many derivatives of 
chitosan have been synthesised,e.g., 
carboxymethyl chitosan which exhibits better 
solubility and moisture retaining property than 
chitosan  [1]. Many chitosan derivatives have 
been found to have antibacterial activity and 
can be used as such, e.g., hydroxypropyl 
chitosan [2]. 
 
 Chitosan is a weak base and a certain 
amount of acid is required to transform the 
glucosamine units into the uncoiled and 
positively charged water-soluble form [3]. At 
neutral pH values, the chitosan molecule will 
loose its charge and therefore precipitate 
from solution [3]. In this regard possibilities 
for the potential use of chitosan as an 
absorption enhancer in the more basic 
environment of the large intestine, colon and 
rectal mucosa are limited. However, potential 
reactive groups make chitosan a versatile 
polymer with unique properties. Chitosan 
derivatives with different physico-chemical 
properties, especially water solubility at 
neutral and basic conditions, will be of 
particular interest, e.g., N-trimethyl chitosan 
chloride is able to increase the transport of 
large hydrophilic compounds [3]. The charge 
density and structural features of this 
derivative of chitosan makes it to act as a 
absorption enhancer across mucosal 
epithelia by opening the tight junctions [3]. 
Chitosan acatate exhibits better micromeritic 
properties than the pharmaceutical binder, 
PVP K30, and as a tablet binder, it could 
produce sustained drug release [4].  
 
Chemical modifications of chitosan have 
been reported. These include interaction with 
salicylic acid when incorporated into chitosan 
films using acetic acid as a solvent/vehicle; 
this, in turn, affected its drug release behavior 
[5]. Spray dried chitosan microspheres, 
loaded with insulin for protein delivery, 
prepared using acetic acid as solvent, also 
showed chenial interaction with the protein 
[6]. Furthermore, studies have been reported 
whereby chitosan was modified to N-trimethyl 
chitosan chloride, carboxymethyl chitosan 
and hydroxyl propyl chitosan [2,3].  
 
Chronic diseases, such as asthma and 
rheumatoid arthritis, if treated via the 
transdermal route, may offer several 
advantages over other routes such as 
prevention of first pass metabolism and high 
bioavailability. However delivery of drugs 
through transdermal drug delivery system is 
limited due to limited absorption through the 
skin. Films produced by casting chitosan 
solution, when applied to skin, often cause 
irritation due to the presence of traces of acid 
except the films are washed first to remove 
traces of acid. Propranolol hydrochloride, 
which was selected for this study, has a 
biological half life of 4h and is, therefore, 
usually administered several times a day. 
Consequently, there is a need to develop a 
dosage form which delivers the drug in a 
sustained fashion. Propranolol hydrochloride 
is subject to an extensive and highly variable 
hepatic first pass metabolism following oral 
administration with a reported systemic 
bioavailability of 15 – 23 %, indicating the 
need for alternative drug delivery modes. 
Hence, in this study, an attempt has been 
made to prepare chitosan acetate 







Propranolol hydrochloride was a gift from M/s 
Strides Arcolab Ltd, Bangalore. Chitosan was 
procured from Vishu Aquatech, Madras, 
India.  All other reagents used were of 
analytical grade.  
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Preparation of chitosan and chitosan 
acetate solution 
 
Chitosan solution (2% w/v) was prepared by 
stirring chitosan in 1% acetic acid using a 
homogeniser until the chitosan dissolved 
completely. Chitosan acetate was prepared 
by mixing 50 ml of the chitosan solution with 
2 ml of acetaldehyde by stirring continuously 
for 3 h at 60 °C. The solution was cooled and 
acetone was added to precipitate chitosan 
acetate [7]. 
 
Fabrication of films 
 
Propranolol hydrochloride [400 mg] was 
added to 100 ml of either chitosan or chitosan 
acetate solution prepared above and stirred 
with a homogeniser for half an hour to 
dissolve the drug. The mixture was poured 
into Petri dish and dried overnight at 40 °C. 
The films produced were peeled from from 
the Pteri dish and washed with 50 % ethanol 
to remove surface-bound traces of acid.  
 
Assessment of drug entrapment 
 
Films of 1 cm
2
 in area were weighed and 
placed in a 100 ml volumetric flask containing 
50 ml of distilled water and kept for 24 h. The 
volume was made up to 100 ml with distilled 
water, filtered and the drug content was 
assayed by measuring the absorbance at 290 
nm using UV spectrophotometer (Schimadzu 
1700) and that of a standard over a 
concentration range of 10 – 40 µg/ml. The 






A film of 1cm
2
 in area was weighed and 
placed in a watch glass containing 
approximately 10ml of water. At regular 
intervals, the membrane was taken out, 
blotted with filter paper and weighed on a 
digital balance. After attaining equilibrium 
weight, the membranes were dried and 
weighed to determine % water absorbed 
which was taken as % swelling. All tests were 
in triplicate. 
Permeability studies  
 
Approx. 1 g of calcium chloride was taken in 
dried vials (2.3 x 4.8 cm) and the films (1 
cm
2
) were tightly fixed over the brim of the 
vials with the aid of an adhesive. The vials 
were accurately weighed and kept in a 
desiccator containing a saturated solution of 
potassium chloride at room temperature. The 
vials were removed and weighed daily for 7 
days. Permeability or water vapor 
transmission rate (WVTR) for chitosan and 
chitosan acetate films were calculated 
formulas in Eq 1.  
 
WVTR = WL/S ………………………….…  (1)  
 
where W is the weight of water transmitted, L 
the thickness of the film and S the film 
surface area [7]. The tests were performed in 
triplicate. 
 
In vitro drug release studies  
 
In vitro drug release was assessed in distilled 
water by means of a Franz diffusion cell with 
the magnetic stirrer set at 100 rpm. The 
amount of drug released was determined by 
withdrawing 5 ml of the dissolution fluid at 
various time intervals over 24 h. The volume 
withdrawn was replaced with an equal 
volume of fresh distilled water to maintain 
sink conditions. The withdrawn samples were 
analysed spectrophotometrically at 290 nm 
using distilled water as blank [10]. All 
determinations were in triplicate. 
 
Fourier transform infra-red spectroscopy 
(FTIR) 
 
FTIR analysis of both chitosan and chitosan 
acetate was performed on a Shimadzu FTIR 
8400S  using KBr pellet to hold the sample 
and was expressed in cm
-1
. The solid pellet 
was prepared using KBr at room 
temperature.   
 
 
Hemant et al  
Trop J Pharm Res, April 2010; 9 (2): 200 
Differential scanning calorimetry (DSC) 
 
   DSC thermograms and thermal transition 
temperatures for chitosan and chitosan 
acetate were obtained and examined using a 
differential scanning colorimeter (DSC Q 100, 
TA Instruments) to determine whether there 
was any interaction between the drug and the 
polymers used. Sample size was 2 - 4 mg 
and the samples were sealed in aluminium 
pans and heated at a rate of 5 
0
C/min in a 
nitrogen gas atmosphere. 
 
Nuclear magnetic resonance (NMR) 
 
13
C NMR studies were carried out on the 
films with an
 
NMR spectrometer (DSX-300, 
Bruker, India) in the solid state at 75Mhz to 
determine whether there were chemical 
interactions between the drug and the 
polymers.   
 
Data analysis  
 
To determine the mechanism of drug release 
from the films, the release data were fitted to 
zero-order, first-order, and Higuchi models 
using the software PCP DissoV-2.08 software 
(Poona College of Pharmacy, Pune, India)  
Comparison of the data obtained for chitosan 
and chitosan acetate was made by Student t-
test at 95 % level of confidence using 






The content of propranolol hydrochloride in 
the films was 0.9 and 1.4 mg/cm
2
 for chitosan 
and chitosan acetate, respectively.  
 
Water absorption (swelling) 
 
As Fig 1 shows, the films prepared with 
chitosan acetate showed nearly 3 times 
greater swelling than chitosan. Swelling was 
as high as 570 and 180 % for chitosan 
acetate and chitosan, respectively.  
 
Table 1: Swelling (%, ±SD) of chitosan and 








1 20.25± 0.43 53.21± 0.56 
2 26.43± 0.63 76.21± 1.19 
3 34.35± 1.32 132.12± 2.34 
4 55.56± 1.34 189.43± 0.57 
5 75.12± 0.32 275.54± 1.19 
6 89.98± 2.32 332.18± 1.21 
7 118.67± 2.54 402.84± 0.57 
8 139.75± 1.21 473.21± 1.12 
9 164.67± 0.57 506.67±2.32 
10 180.46±2.50 570.31± 1.19 
 
Water vapor transmission rate   
 
The water vapor transmission (or 
permeability) data showed that films prepared 
from chitosan acetate exhibited moisture 









/ day for 
chitosan. Thus, chitosan acetate films were 
approx. six times more permeable than 
chitosan films.  
 
In vitro drug release  
 
Fig 1 shows the in vitro drug release pattern 
of chitosan and chitosan acetate films. The 
data indicate that drug release from chitosan 
acetate films was higher (p < 0.05) than from 
chitosan films.  The drug release data of both 
chitosan and chitosan acetate films showed a 
good fit to the Higuchi model with r
2
 value of 




The FTIR spectra of chitosan and chitosan 
acetate, shown in Fig 2, exhibited broad 
peaks in the range of 3450 - 3400cm
-1. 
These 
peaks were assigned to OH stretching, 
indicating intermolecular hydrogen bonding. 
The spectra also overlapped in the same 
region  of NH  stretching.  The C-O stretching 
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Figure 1: In vitro release pattern of chitosan 
(■) and chitosan acetate (□) films 
 
peak near 1655 cm
-1
 (representing the 
structure of N-acetylglucosamine) as well as 
the NH2 stretching peak at 1600 cm
-1 
(representing the glucosamine functional 
group) were exhibited in the spectrum of 
chitosan. In the spectrum of chitosan acetate, 
the peak near 1655 cm
-1 
disappeared but a 
strong peak at 1550-1600 cm
-1 
and a weak 
peak near 1400 cm
-1 
region appeared which 
are attributed to asymmetric and symmetric 
carboxylate anion stretching. These peaks 
provide evidence of the conversion of 




The DSC thermograms in Fig 3 indicate 
conversion of chitosan to the acetate 
derivative did not affect its thermal properties 
as the decomposition temperature of chitosan 
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NMR spectroscopy 
 
Examination of the 
13
C NMR spectrum of 
chitosan acetate shows resonance at 50 – 
110 ppm which was attributed to the 
presence of glocosamine units. The 
resonance at 180 ppm was assigned to 
carbonyl carbon while the one at 24ppm was 
assigned to CH3 carbon which represents 
acetate functionality. As a result of the high 
degree of deacetylation of chitosan, the 
resonance assigned to CH3 carbon at 24 
ppm, N acetyl glucosamine units at 174 ppm, 
and carbonyl carbon at 180 ppm could hardly 
be observed in chitosan spectra [4] while 
these were clearly visible in chitosan acetate 




To form chitosan acetate, the free amino 
group of chitosan reacted with an aldehyde in 
the presence of acid to form Schiff’s base. 
Acetaldehyde was selected based on its film-
forming capability with chitosan. Chemically-
modified chitosan is capable of producing 
membranes with superior properties such as 
high efficiency in drug loading, permeability 
and drug release due to changes in the 
polymeric interpenetrating network in the 
grafted polymer.  
 
Various films have been used in the delivery 
of various drugs as transdermal delivery 
systems [7,15]. From the results obtained, it 
is clear that propranolol hydrochloride was 
loaded into the transdermal film in desired 
amount to give therapeutic levels of the drug. 
The swelling and permeability (WVTR) of 
films were good as documented in the results 
section while release studies showed that the 
drug was released in a sustained manner 
over 24 h with up to 80 % of the loaded drug 
released.  
 
Drug loading was higher for chitosan acetate 
due to the formation of Schiff’s bases with 
acetaldehyde which generated more space 
within the polymeric network for trapping the 
drug. Since chitosan is insoluble in water, the 
films did not dissolve but swelled, but 
swelling was greater for chitosan acetate 
films due to its loose polymeric network. The 
formation of Schiff’s base with acetaldehyde 
and the consequent generation of larger 
space within the polymeric network explain 
why chitosan acetate films showed higher 
permeability than chitosan films. This also 
explains why drug release was higher for 
chitosan acetate than chitosan films. 
 
FTIR spectra support the claim that chitosan 
was actually converted to chitosan acetate 
and that the main peaks remained the same 
without any change in their respective 
wavelengths. The DSC thermograms also 
buttress the fact that there was no chemical 
interaction between the drug and the 
polymers used while 
13
C NMR spectra 
confirmed that chitosan was converted into 
chitosan acetate. The high linearity of the 
regression coefficient, when the release data 
were fitted to the Higuchi model, indicate that 
drug release was matrix diffusion-controlled. 
This resulted in sustained release of the drug 




Chitosan acetate has some advantages over 
chitosan including higher drug entrapment, 
greater water permeability and swelling, and 
faster in vitro drug release. These 
advantages should make chitosan acetate 
films suitable for propranolol hydrochloride 
delivery via the transdermal route, a route 
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